Læknablaðið - 15.10.1997, Blaðsíða 43

LÆKNABLAÐIÐ 1997; 83
663
temporal oxygen metabolism in Alzheimer’s disease
shown by PET. J Nucl Med 1996; 37: 1159-65.
21. Simonian NA, Coyle JT. Oxidative Stress in Neurode-
generative Diseases. Ann Rev Pharmacol Toxicol 1996;
36: 83-106.
22. Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E,
Shinobu LA, et al. Mutation in mitochondrial cyto-
chrome c oxidase genes segregate with late-onset Alz-
heimer disease. Proc Natl Acad Sci 1997; 94: 4526-31.
23. Sandbrink R, Hartmann T, Masters CL, Beyreuther K.
Genes contributing to Alzheimer’s disease. Mol Psychi-
atry 1996; 1: 27-40.
24. Muramatsu T, Matsushita S, Arai H, Sasaki H, Higuchi
S. Alpha 1-antichymotrypsin gene polymorphism and
risk for Alzheimer’s disease. J Neural Transm 1996:103:
1205-10.
25. Schofield PW, Tang M, Marder K, Bell K, Dooneief G,
Chun M, et al. Alzheimer's disease after remote head
injury: an incidence study. J Neurol Neurosurg Psychia-
try 1997; 62: 119-24.
26. Savory J, Exley C, Forbes WF, Huang Y, Joshi JG,
Kruck T, et al. Can the controversy of the role of alu-
minium in Alzheimer’s disease be resolved? What are
the suggested approaches to this controversy and meth-
odological issues to be considered? J Toxicol Environ
Health 1996; 48: 615-35.
27. Tanzi RE. Neuropathology in the Down’s Syndrome
Brain. Nat Med 1996; 2: 31-2.
28. Wilson DM, Binder LI. Free Fatty Acids Stimulate the
Polymerization of Tau and Amyloid (3 Peptides. In Vitro
Evidence for a Common Effector of Pathogenesis in
Alzheimer’s Disease. Am J Pathol 1997; 150: 2181-95.
29. Saitoh T, Mook-Jung I. Commentary: Is Understanding
the Biological Functions of APP Important in Under-
standing Alzheimer’s Disease? Alzheimer’s Dis Rev
1996; 1: 30-6.
30. Connor B, Young D, Lawlor P, Gai W, Waldvogel H,
Faull RL, et al. Trk receptor alteration in Alzheimer’s
disease. Brain Res Mol Brain Res 1996; 42: 1-17.
31. Wolozin B, Iwasaki K, Vito P, Ganjei JK, Lacaná E,
Sunderland T, et al. Participation of Presenilin 2 in
Apoptosis: Enhanced Basal Activity Conferred by an
Alzheimer Mutation. Science 1996; 274: 1710-3.
32. McShea A, Harris PLR, Webster KR, Wahl AF, Smith
MA. Short Communication: Abnormal Expression of
the Cell Cycle Regulators P16 and CDK4 in Alzheimer’s
Disease. Am J Pathol 1997; 150: 1933-9.
33. O’Barr S, Schultz J, Rogers J. Expression of the pro-
tooncogene bcl-2 in Alzheimer’s Disease. Neurobiol
Ageing 1996; 17: 131-6.
34. Neve R. Amyloid Discussion Group: APP and Signall-
ing. Harvard Medical School, 1996: http://www.
alzforum.org/members/forums/amyloid/signalling.html
35. Citron M, Westaway D, Xia W, Carlson G, Diehl T,
Levesque G, et al. Mutant presenilins of Alzheimer’s
disease increase production of 42-residue amyloid beta-
protein in both transfected cells and transgenic mice.
Nat Med 1997; 3: 67-72.
36. Illingworth RD. Lipoprotein Metabolism. Am J Kidney
Disease 1993; 22: 90-7.
37. Mahley RW. Apolipoprotein E: Cholesterol Transport
Protein with Expanding Role in Cell Biology. Science
1988; 240: 622-30.
38. Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye
JA, Bird TD, et al. Gender difference in apolipoprotein
E-associated risk for familial Alzheimer disease: a pos-
sible clue to the higher incidence of Alzheimer’s disease
in women. Am J Hum Genet 1996; 58: 803-11.
39. Davignon J, Gregg RE, Sing CF. Apolipoprotein E
polymorphism and Atherosclerosis. Arteriosclerosis
1988; 8: 1-21.
Enskt íslenskt orðasafn
A|3 (amyloid (3-peptide) = amýloid beta peptíð
ACT-A (antichymotrypsin A) = andkýmó-
trýpsín A
ApoE (apolipoprotein E) = apólípóprótín E
App ((3-amyloid precursor protein) = (3-amýl-
oid forveraprótín
C100 (C-end of App) = innanfrumuhluti (C-
endi) App
FAD (familial Alzheimer’s disease) = ættlæg-
ur Alzheimers sjúkdómur
GAG (glycosaminosglycan) = glýkósamínó-
glýkan
HLA-A (human leukocyte antigen A) = vefja-
flokkasameind af gerð A
LDL (low-density-lipoprotein) = lágþéttni
lípóprótín
MAP (microtubule associated protein) = ör-
píplutengd prótín
mApp (membrane-bound App) = himnu-
bundið App
MEKK (MAP kinase’s kinase) = MAP kínasa
kínasi
NFT (neurofibrillary tangles) = taugatrefja-
flækjur
NP (neuritic plaques) = taugaflögur
Pak (p21 activated kinase) = prótín (21kD)
espaður kínasi
PET (positron emission tomography) =
jáeindar útgeislunar sneiðmyndataka
Ps (presenilin) = Ps-prótín
sApp (secreted App) = seytt App
VLDL-R (very-low-density-lipoprotein R) =
ofurlágþéttni lípóprótín R